From PIQ website. Dec 2018: CEO Dr. Lipscombe
“Indeed,we see the personalised medicine market more than doubling in size within thenext 4 years. This is exactly where Proteomics International's technologyplatform is focused, both for developing new tests or helping to monitor drugtherapies.
Forexample, diagnostic tests can be essential for the safe and effective use oftherapeutics (companion diagnostic), or may help weigh up the risks andbenefits of a treatment without restricting drug access (complementarydiagnostic). A test like PromarkerD could act as a complementary diagnostic forthe more than 20 new drugs being developed for diabetic kidney disease.”
Ann: Appendix 4C - March 2019 Quarterly Report, page-14
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.015(4.92%) |
Mkt cap ! $47.42M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 28.5¢ | $191.2K | 643.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53694 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 51000 | 2 |
View Market Depth
| Last trade - 15.36pm 26/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |